Page 99 - Memoria FEHH - SEHH 2017
P. 99
PROGRAMA ESPAÑOL DE TRATAMIENTOS EN HEMATOLOGÍA (PETHEMA)
MEMORIA ANUAL 2017
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
• Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Brunet S, Bergua J, Tormo M, García-Boyero R, Sarrà J, Del Potro E, Grande C, Barba P, Bernal T, Amigo ML, Grau J, Cervera J, Feliu E; PETHEMA Group, Spanish Society of Hematology. Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Leuk Lymphoma. 2017 Jan; 58(1):145-52.
• Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Blanco ML, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu M, Ana F, Sanz GF, Florensa L; Grupo Español de Síndromes Mielodisplásicos (GESMD). Enumerating Bone Marrow Blasts from Nonerythroid Cellularity Improves Outcome Prediction in Myelodysplastic Syndromes and Permits a Better Definition of the Intermediate Risk Category of the Revised International Prognostic Scoring System (IPSS-R). Am J Hematol. 2017 Jul;92(7):614-21.
• Drusbosky L, Medina C, Martuscello R, Hawkins KE, Chang M, Lamba JK, Vali S, Kumar A, Singh NK, Abbasi T, Se- keres MA, Mallo M, Sole F, Bejar R, Cogle CR. Computational drug treatment simulations on projections of dys- regulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. Leuk Res. 2017;52:1-7.
• Janusz K, Del Rey M, Abáigar M, Collado R, Ivars D, Hernández-Sánchez M, Valiente A, Robledo C, Benito R, Díez- Campelo M, Ramos F, Kohlmann A, Cañizo CD, Hernández-Rivas JM. A two-step approach for sequencing spli- ceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts. Leuk Res. 2017;56:82-7.
• Montoro J, Robledo C, Zamora L, Valcárcel D, Ramos F. Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis. Ann Hematol. 2017;96(2):317-8.
• Nomdedeu M, Pereira A, Ramos F, Valcárcel D, Costa D, Arnan M, Calvo X, Pomares H, Luño E, Díaz-Campelo M, Colla- do R, de Paz R, Falantes JF, Pedro C, Marco J, Oirtzabal I, Sánchez-García J, Tormo M, Cedena MT, Nomdedeu B, Sanz G; Spanish MDS Group. Excess mortality in the myelodysplastic syndromes. Am J Hematol. 2017;92(2):149-54.
• Palau A, Mallo M, Palomo L, Rodríguez-Hernández I, Diesch J, Campos D, Granada I, Juncà J, Drexler HG, Solé F, Buschbeck M. Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia. Genes Chromosomes Cancer. 2017;56(3):243-52.
• Palomo L, Fuster-Tormo F, Alvira D, Ademà V, Armengol MP, Gómez-Marzo P, Haro N, Mallo M, Xicoy B, Zamora L, Solé F. Inspecting targeted deep sequencing of whole genome amplified DNA versus fresh DNA for so- matic mutation detection: A genetic study in myelodysplastic syndrome patients. Biopreserv Biobank. 2017 Aug;15(4):360-5.
• Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis- Stimulating Agents. J Clin Oncol. 2017 May 10;35(14):1591-7. PMID: 28350519.
• García-Gutiérrez V, Gómez-Casares MT, Puerta JM, Alonso-Domínguez JM, Osorio S, Hernández-Boluda JC, Collado R, Ramírez MJ, Ibáñez F, Martín ML, Rodríguez-Gambarte JD, Martínez-Laperche C, Gómez M, Fiallo DV, Redon- do S, Rodríguez A, Ruiz-Nuño C, Steegmann JL, Jiménez-Velasco A; Spanish Group of Chronic Myeloid Leukemia (GELMC). A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia. PLoS One. 2017 Mar 9;12(3):e0173532.
99
